News on technologies and applications for point-of-care testing.
Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.
The firm said declines across most business areas were slightly offset by increases in sales of sample collection devices.
Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.
CEO Doug Bryant noted, in particular, what he expects will be a hunger for rapid protein-based antigen tests for the coronavirus that the market currently can't fill.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
